Calidi Biotherapeutics, Inc.
1.4900-0.03 (-1.97%)
Oct 29, 4:00:00 PM EDT · NYSE American · CLDI · USD
Key Stats
Market Cap
7.97MP/E (TTM)
-Basic EPS (TTM)
-0.20Dividend Yield
0%Recent Filings
8-K
Calidi forms expert SAB for CLD-401
Calidi Biotherapeutics announced on October 22, 2025, the formation of a Scientific Advisory Board to accelerate development of its RedTail platform and push CLD-401 into clinical trials. The board features experts like former Pfizer CMO Mace Rothenberg and virotherapy leader David Curiel, bringing deep oncology and immunotherapy know-how. This move bolsters Calidi's push for systemic genetic medicines targeting metastatic cancers. Yet risks loom in funding and trial outcomes.
8-K
Updated investor presentation released
8-K
Calidi closes $6.9M offering
Calidi Biotherapeutics closed an underwritten public offering on August 21, 2025, selling 1,922,764 common stock units and 1,528,000 pre-funded warrant units at $2.00 and $1.999 each, yielding gross proceeds of $6.9 million after full exercise of the over-allotment option. Funds will support working capital, general corporate purposes, pre-clinical studies, and clinical trial preparation amid tough market conditions. Warrants expire in five years at $2.00 exercise price. Lock-up restrictions bind insiders for 90 days.
8-K
Exec separation agreement signed
Calidi Biotherapeutics finalized a separation agreement with Dr. Boris Minev on August 8, 2025, following the elimination of his President, Medical and Scientific Affairs role effective July 29, 2025. The deal includes a $100,000 bonus for NNV1 and SNV1 IND approvals and $187,500 in severance paid over six months, plus six months of COBRA premiums. This streamlines executive structure amid biotech development pushes. Equity vesting halts post-separation.
10-Q
Q2 FY2025 results
Calidi Biotherapeutics narrowed its Q2 operating loss to $5.7 million, a slight improvement from $5.8 million a year ago, while year-to-date losses eased 17% to $10.8 million amid tighter spending on legal and insurance costs. Research expenses ticked up 20% quarterly to $2.6 million, driven by consulting and preclinical work on oncolytic virus platforms, yet overall cash burn moderated as the firm raised $10.1 million through offerings. Cash dipped to $5.3 million by quarter-end, with $1.4 million in debt mainly from related-party notes at 14% rates; free cash flow isn't disclosed in the 10-Q. The reverse stock split in August aims to stabilize trading, but ongoing litigation over executive claims poses a persistent drag.
BOLT
Bolt Biotherapeutics, Inc.
5.86+0.14
CALC
CalciMedica, Inc.
2.97-0.10
CBIO
Crescent Biopharma, Inc.
12.50+0.00
CDTX
Cidara Therapeutics, Inc.
104.68-0.46
CRBU
Caribou Biosciences, Inc.
2.37-0.10
CYDY
CytoDyn Inc.
0.24-0.01
ESLA
Estrella Immunopharma, Inc.
2.46-0.06
MBIO
Mustang Bio, Inc.
1.47-0.03
NWBO
Northwest Biotherapeutics, Inc.
0.23-0.02
VIR
Vir Biotechnology, Inc.
5.91-0.52